Publications

Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021.

Uyoga, S; ADETIFA, IM O; OTIENDE, M; Yegon, C; AGWEYU, A; Warimwe, GM; SCOTT, JA G;

2021

Journal of the American Medical Association, (2021).326 14 10.1001/jama.2021.15265.

The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant.

HODGSON, D; FLASCHE, S; JIT, M; KUCHARSKI, AJ; CMMID COVID-19 Working Group,; Centre for Mathematical Modelling of Infectious Di,;

2021

Eurosurveillance, (2021).26 20 10.2807/1560-7917.ES.2021.26.20.2100428.

Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.

Lazarus, JV; Ratzan, SC; Palayew, A; Gostin, LO; LARSON, HJ; Rabin, K; Kimball, S; El-Mohandes, A;

2021

Nature medicine, (2021).27 2 10.1038/s41591-020-01226-0.

Inequities in childhood immunisation coverage associated with socioeconomic, geographic, maternal, child, and place of birth characteristics in Kenya.

Allan, S; ADETIFA, IM O; ABBAS, K;

2021

BMC infectious diseases, (2021).21 1 10.1186/s12879-021-06271-9.

Evaluation of a Campylobacter jejuni N-glycan-ExoA glycoconjugate vaccine to reduce C. jejuni colonisation in chickens.

Vohra, P; Chintoan-Uta, C; Bremner, A; MAURI, M; TERRA, VS; CUCCUI, J; WREN, BW; Vervelde, L; Stevens, MP; Glycoengineering of Veterinary Vaccines Consortium,;

2021

Vaccine, (2021).39 51 10.1016/j.vaccine.2021.10.085.

Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.

Drolet, M; Laprise, J-F; Martin, D; JIT, M; Bénard, É; Gingras, G; Boily, M-C; Alary, M; Baussano, I; Hutubessy, R; Brisson, M;

2021

The Lancet. Infectious diseases, (2021).21 11 10.1016/S1473-3099(20)30860-4.

Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.

Leach, AJ; MULHOLLAND, EK; Santosham, M; Torzillo, PJ; McIntyre, P; Smith-Vaughan, H; Wilson, N; Arrowsmith, B; Beissbarth, J; Chatfield, MD; Oguoma, VM; Morris, PS;

2021

BMC pediatrics, (2021).21 1 10.1186/s12887-021-02552-z.

The role of maturity in adolescent decision-making around HPV vaccination in France.

KARAFILLAKIS, E; Peretti-Watel, P; Verger, P; CHANTLER, T; LARSON, HJ;

2021

Vaccine, (2021).39 40 10.1016/j.vaccine.2021.08.096.

Vaccine safety in the next decade: why we need new modes of trust building.

LARSON, HJ; Sahinovic, I; Balakrishnan, MR; Simas, C;

2021

BMJ global health, (2021).6 Suppl 10.1136/bmjgh-2020-003908.

How can the public health impact of vaccination be estimated?.

Londono, SE; Li, X; Toor, J; Villiers, MD; Nayagam, S; Hallett, T; Abbas, K; JIT, M; KLEPAC, P; Jean, K; Garske, T; Ferguson, N; Gaythorpe, K;